Endocrine, metabolic & immune disorders drug targets最新文献

{"title":"A Comparative Analysis of COVID-19-Associated and Non-COVID-19-Associated Mucormycosis.","authors":"Süheyla Kömür, Aslıhan Candevira, Ayşe Seza İnala, Ferit Kuşcua, Behice Kurtarana, Funda Memişoğlub, İlkay Karaoğlanc, Yeşim Taşovaa","doi":"10.2174/0118715303335275250116055824","DOIUrl":"https://doi.org/10.2174/0118715303335275250116055824","url":null,"abstract":"<p><strong>Background: </strong>COVID-19-associated Mucormycosis (CAM) has emerged as a significant complication during the COVID-19 pandemic. However, there is a lack of comprehensive comparative studies with non-COVID-associated mucormycosis (NCM).</p><p><strong>Objective: </strong>This study aims to compare the clinical characteristics, risk factors, and outcomes of CAM and NCM to enhance the understanding and management of these infections, particularly during the COVID-19 pandemic.</p><p><strong>Method: </strong>A retrospective multicenter study was conducted at Cukurova University, Malatya İnönü University, and Gaziantep University. We analyzed and compared cases of CAM and NCM diagnosed between January 2018 and February 2022. Data were collected from the infectious diseases and clinical microbiology departments, including demographic details, underlying conditions, treatment regimens, and outcomes.</p><p><strong>Results: </strong>A total of 38 cases were analyzed, with 21 cases of COVID-19-associated mucormycosis (CAM) and 17 cases of non-COVID-19-associated mucormycosis (NCM). The key findings of the study were as follows: CAM was strongly associated with corticosteroid use (p<0.001) and diabetes (p=0.001), while NCM cases were more frequently linked to malignancy and neutropenia (p<0.05). Clinically, CAM cases had a higher incidence of cavernous sinus involvement and bone destruction (p=0.003) compared to NCM cases. However, there was no significant difference in overall survival between the CAM and NCM groups (p=0.201).</p><p><strong>Conclusion: </strong>The study highlights the critical role of corticosteroid use and diabetes as prominent risk factors for CAM. Timely diagnosis and intervention are essential to prevent severe complications, such as cavernous sinus involvement and bone destruction. These findings emphasize the need for tailored management strategies for CAM in the context of COVID-19, with particular attention to these risk factors.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"1-Deoxynojirimycin Ameliorates Diabetic Liver Injury by Regulating AMPK/SIRT1 and Oxidative Stress in db/db Mice.","authors":"Yao Li, Yu Cao, Yun-Yuan Tian, Wen-Wen Chen, Juan Wang, Meng-Meng Zhang, Si-Wang Wang, Yan-Hua Xie","doi":"10.2174/0118715303327499250104221937","DOIUrl":"https://doi.org/10.2174/0118715303327499250104221937","url":null,"abstract":"<p><strong>Background: </strong>Patients with diabetic liver injury are in the dilemma of lowering glucose and protecting liver function. This study aimed to uncover the protective effect and mechanism of 1-deoxynojirimycin (1-DNJ), an alpha-glucosidase inhibitor, against diabetic liver injury.</p><p><strong>Methods: </strong>The db/db mice were gavaged with 25 mg/kg, 50 mg/kg, and 100 mg/kg of 1-DNJ for 8 weeks. At the end of the administration, the serum and liver were isolated for further detection. The biochemical indices including TC, TG, LDL-C, AST, ALT, and TBiL were detected in serum. The livers were further analyzed with H&E, oil red, and Masson staining, and the amount of ROS in the liver was detected with probe dihydroethidium. Western blot was used to analyze the levels of proteins involved in fibrosis, oxidative stress, and AMPK/SIRT1 signaling pathway in the liver.</p><p><strong>Results: </strong>1-DNJ administration reduced body weight, liver coefficient, and TC, TG, LDL-C, AST, ALT, and TBiL in db/db mice. H&E and oil red staining showed that 1-DNJ ameliorated hepatocellular ballooning degeneration and lipid deposition in the liver. Moreover, 1-DNJ reduced the hepatic collagen fiber deposition and the protein expression of α-SMA and Collagen I. Further assays revealed that 1-DNJ treatment reduced the ROS level, up-regulated the proteins expression of SOD2, HO-1, NQO-1, p-AMPK/AMPK, p-ACC/ACC, and SIRT1 proteins, and down-regulated the expression of SREBP-1 and SCD-1 proteins in the liver.</p><p><strong>Conclusion: </strong>1-DNJ improves liver function, lipid deposition, and fibrosis of diabetic liver injury in db/db mice by regulating the AMPK/SIRT1 pathway to improve glucose-lipid metabolism and oxidative stress.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Chrysin Nanocrystal on the Thyroid Gland of Rats Exposed to Chlorpyrifos.","authors":"Tahereh Farkhondeh, Fatemeh Ahrari, Shahnaz Rajabi, Effat Alemzadeh, Behzad Mesbahzadeh, Maryam Rezaei, Sara Ziafati Majidi, Saeed Samarghandian","doi":"10.2174/0118715303329277250120104421","DOIUrl":"https://doi.org/10.2174/0118715303329277250120104421","url":null,"abstract":"<p><strong>Background: </strong>Chlorpyrifos (CPF) is an organophosphate insecticide that is mostly used in agriculture for pest control.</p><p><strong>Aim: </strong>This investigation aimed to evaluate the possible protective role of chrysin nanocrystals on thyroid gland hormones and histology in male rats after exposure to a high dose of chlorpyrifos.</p><p><strong>Method: </strong>Rats were randomly divided into 6 groups (6 rats in each group): 1. healthy control group, 2. treated with chrysin nanocrystal (5 mg/kg), 3. treated with chrysin nanocrystal (10 mg/kg), 4. treated with chrysin nanocrystal (5 mg/kg) + chlorpyrifos, 5. treated with chrysin nanocrystal (10 mg/kg) + chlorpyrifos, and 6. treated with chlorpyrifos (30 mg/kg). After 15 days of intervention, rats were anesthetized, and blood samples were taken from the heart to measure thyroid hormones. Then, the thyroid gland was isolated and stored in 10% formalin for histopathological studies. Thyroid samples were also stored at -80 ° C for measuring oxidative stress parameters.</p><p><strong>Result: </strong>A significant reduction was observed in the serum concentrations of T3 and T4 in all treated groups compared with the control group (p < 0.01). In addition, hormone level examination revealed no statistically significant (p ˃ 0.05) changes in plasma TSH concentration in any of the groups. The treatment with CPF and chrysin nanocrystal did not affect the levels of oxidative biomarkers (MDA, GSH, and NO) in thyroid glands. Photomicrographs of a histological section of the thyroid gland showed vacuolar degenerated follicle epithelium and missing colloids in the histological section of the thyroid gland of all groups.</p><p><strong>Conclusion: </strong>Our findings demonstrated that the oral administration of chrysin nanocrystals could not inhibit the toxic effect of a high dose of CPF on the thyroid gland in the rats.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Empagliflozin and Arterial Stiffness in Patients with Type 2 Diabetes: A Real-World Case-Control Study.","authors":"Francesco Tassone, Cinzia Ferreri, Arianna Rossi, Giorgio Borretta, Guido Pastorini, Fabio Anastasio, Mauro Feola","doi":"10.2174/0118715303372020250131060159","DOIUrl":"https://doi.org/10.2174/0118715303372020250131060159","url":null,"abstract":"<p><strong>Background: </strong>Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated beneficial cardiovascular and renal effects in patients with type 2 diabetes mellitus (T2DM).</p><p><strong>Objective: </strong>The objective of this case-control study was to evaluate the efficacy of empagliflozin in modifying the arterial stiffness in type 2 diabetic patients.</p><p><strong>Methods: </strong>Pulse wave velocity (PWV) and other parameters of arterial stiffness were assessed at baseline and after three months of empagliflozin treatment in 16 consecutive outpatients with type 2 diabetes mellitus (T2DM) exhibiting normal left ventricular function and no signs of heart failure. A control group of 16 T2DM outpatients not treated with SGLT2 inhibitors was used for comparison.</p><p><strong>Results: </strong>Duration of diabetes mellitus and sex distribution did not differ between groups. Patients in the empagliflozin group were younger compared to controls (64.1 ± 8.68 vs 74.45 ± 8.13, p < 0.05). At 3-month follow-up, empagliflozin treatment significantly reduced HbA1c (7.9 ± 0.78 vs 7.04 ± 1.09%, p < 0.008). Empagliflozin significantly improved PWV compared to controls (from 13.2 ± 2.0 m/sec to 12.3 ± 1.8 m/sec; P = 0.001; in the control group 12.8 ± 2.3m/s to 13.2 ± 2.4, p = ns, with age and HbA1c as covariates) as well as body weight that significantly reduced (86.75 ± 16.16 kg vs 81.71 ± 16.5 kg, p =0.001) and BMI (30.48 ± 5.4 versus 28.75 ± 5.66 kg/m2, p < 0.002) in comparison to controls. Estimated glomerular filtration rate (eGFR) remained unchanged whereas a significant improvement of urine Albumin to Creatinine ratio with empagliflozin emerged (17.8 ± 46.8 vs 12.2 ± 35.7 mg/mmol, p = 0.049).</p><p><strong>Conclusion: </strong>In this clinical study, mid-term treatment with empagliflozin in patients with type 2 diabetes mellitus (T2DM) resulted in a significant reduction in arterial stiffness. Additionally, the improvement in the urine albumin-to-creatinine ratio suggests a potential enhancement in endothelial function.</p>.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of the Prognosis and Treatment Responses Based on the Characteristics of Disulfidptosis-Related Genes in Patients with Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma.","authors":"Min Kang, Sha Jiang, Huihui Chen, Youhua Xu, Hui Mo","doi":"10.2174/0118715303374396250129111340","DOIUrl":"https://doi.org/10.2174/0118715303374396250129111340","url":null,"abstract":"<p><strong>Background: </strong>Disulfidptosis is a new type of regulatory cell death (RCD), but the pathophysiological functions and mechanisms of DRGs in CESC remain to be examined.</p><p><strong>Aims: </strong>This study explored the mutation status of disulfidptosis-related genes (DRGs) in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC).</p><p><strong>Objective: </strong>After analyzing the mutation profiles of DRGs in CESC, this study established a prognostic model for CESC and also explored the differences in immune infiltration (accumulation of immune system cells in tissues or organs), related enriched pathways, and drug sensitivity between high-risk and low-risk CESC groups.</p><p><strong>Methods: </strong>The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) were accessed to source related data. The mutation profiles of DRGs in CESC were analyzed using Mutect2 software, and disulfidptosis scores were calculated by ssGSEA. WGCNA was performed to identify modular genes, which were further filtered and used to formulate a risk model by applying the survival and glmnet packages. Low- and high-risk groups of CESC patients were classified using the survminer package. GSEA was performed to conduct pathway analysis, and immune infiltration was assessed using the MCPcounter package, ESTIMATE, and TIMER algorithms. Finally, immunotherapy response and drug sensitivity were analyzed using the TIDE method and the pRRophetic package, respectively.</p><p><strong>Results: </strong>Except for NDUFA11, ARL6IP5, EPM2AIP1, GBE1, RBM38, ULK4, and ZBTB47 were found to be the DRGs significantly mutated in CESC. The six genes were integrated to develop a RiskScore model with a relatively high Area Under the Curve (AUC) value. Significant differences between the two risk groups were determined, indicating that the model was highly reliable. Notably, the low-risk group was enriched in energy metabolism-correlated pathways, while the high-risk group was primarily enriched in immune-correlated pathways. The high-risk group showed higher immune cell activity, higher TIDE score, and more B cells than the low-risk group. Drug sensitivity study revealed that the high-risk group was more sensitive to chemotherapy drugs.</p><p><strong>Conclusion: </strong>This study provides novel insights into CESC prognosis, immunotherapy, and drug development, contributing to the clinical treatment for CESC.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abnormal Elevation of the Expression of Costimulatory Molecule CD226 in Graves' Disease: Two Cross-Sectional Studies.","authors":"Zhaowei Huang, Xuerong Liu, Tiantian Cai, Yanfei Jiang, Yuqing Wu, Xinwei Zhang, Rong-Hua Song, Jin An Zhang","doi":"10.2174/0118715303337480250107052116","DOIUrl":"https://doi.org/10.2174/0118715303337480250107052116","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the differential expression of the co-stimulatory molecule CD226 in lymphocytes from patients with New-Onset Graves' Disease (NOGD) and its correlation with clinical indicators.</p><p><strong>Methods: </strong>Sixty-eight participants were recruited for the discovery experiment (NOGD: healthy control (HC) = 39:29). Peripheral Blood Mononuclear Cells (PBMCs) were isolated. Flow cytometry was performed to detect CD226 expression on multiple lymphocyte subtypes. CD226 mRNA expression in PBMCs was detected by qPCR. Fifty-eight participants were recruited for the validation experiment (NOGD: HC=35:23). CD4+ T cells were isolated, and the level of CD226 mRNA in CD4+ T cells was detected. Five cases of each of Graves' disease (GD) thyroid and control thyroid were collected for CD226 immunohistochemical staining.</p><p><strong>Results: </strong>CD226 expression was the highest in monocytes (NOGD: 94.1% vs. HC: 94.8%) and the lowest in CD8+ T cells (NOGD: 65.3% vs. HC: 64.9%). Compared with HC, CD226 expression on the CD4+ T cells increased in the peripheral blood of NOGD patients and correlated with TPO-Ab. Meanwhile, CD226 mRNA levels were elevated in CD4+ T cells and positively correlated with TR-Ab. CD226 expression was significantly increased in the thyroid tissues of GD patients.</p><p><strong>Conclusion: </strong>This study demonstrates for the first time the elevated expression of CD226 in CD4+ T cells and thyroid tissue of NOGD. The abnormal elevation of CD226 is correlated with clinical indicators. It suggests that the co-stimulatory molecule CD226 is involved in the pathogenesis of GD.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative Analysis of Metabolomic and Transcriptomic Data Reveals Metabolic Signatures and Major Metabolic Pathways in Primary Aldosteronism.","authors":"Xiaomei Lai, Tingting Yang, Chaoping Wei, Shuangbei Zhu, Jianling Li","doi":"10.2174/0118715303361250250119035029","DOIUrl":"https://doi.org/10.2174/0118715303361250250119035029","url":null,"abstract":"<p><strong>Objective: </strong>Primary aldosteronism (PA) is the most common secondary hypertension. In this study, we performed the pathway enrichment analysis based on metabolomics and transcriptomic data to find the metabolic perturbations in PA, which could provide new targets for PA and further understand the biology of PA.</p><p><strong>Methods: </strong>24 PA patients and 24 healthy adults served as the control group in this study. Six participants were chosen from each group to have their peripheral blood and serum samples analyzed for omics investigations. Another eighteen participants' peripheral blood samples were selected for further validation of the RNA-sequencing results.</p><p><strong>Results: </strong>Transcriptomic analyses found 518 differentially expressed genes (DEGs), and 339 remarkably differential metabolites (DMs) were identified by untargeted metabolomics. The pathway enrichment analysis was performed by combining with the omics analysis data. We also focused on analyzing metabolic pathways that repeatedly occur and constructed possible genemetabolic networks. A total of 5 genes and 11 metabolites showed significant changes in altered 3 lipid metabolic pathways. Furthermore, the expressions of these genes were verified by qRT-PCR.</p><p><strong>Conclusion: </strong>The combination of metabolomic and transcriptomic data can give a comprehensive picture of unique illness markers and preliminary knowledge of the molecular abnormalities underpinning PA. These findings may point to viable targets for creating treatments.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transporter Associated with Antigen Processing Proteins (TAP-1 and TAP-2) Gene Expression of MHC-I Downregulated in Oral Squamous Carcinoma.","authors":"Vijay Singh, Shailendra Dwivedi, Ruchika Agrawal, Mohan Raj Ps, Akash Bansal, Akash Agarwal, Sanjeev Misra","doi":"10.2174/0118715303344715241225184322","DOIUrl":"https://doi.org/10.2174/0118715303344715241225184322","url":null,"abstract":"<p><strong>Background: </strong>TAP-1 and TAP-2 are crucial proteins for loading antigenic peptides after proteasome-mediated endogenous processing of the MHC-I (Major Histocompatibility Complex- I) pathway. Our study aimed to explore the Transporter Associated with Antigen Processing proteins (TAP-1 and TAP-2) in oral squamous cell carcinoma and premalignant oral lesions.</p><p><strong>Methods: </strong>We recruited a total of 135 subjects from the outpatient department of the ENT unit of our institute. Real-time Polymerase Chain Reaction (PCR) was used to evaluate the levels of TAP-1 and TAP-2 gene expression in pre-cancerous and oral squamous carcinoma samples. Additionally, we measured the circulating levels of inflammatory markers using an automated biochemistry analyzer.</p><p><strong>Results: </strong>In the current study, we found that the subjects with oral squamous cell carcinoma had lower expressions of the TAP 1 and TAP 2 genes than precancerous oral subjects of OSMF, leukoplakia, and OLP. In oral squamous carcinoma subjects, we found a 1.7- and 2.1-fold change in gene expression of TAP-1 and TAP-2, respectively, compared to control subjects. Furthermore, we observed an increase in levels of metabolic inflammatory biomarkers of CRP, ESR, and ferritin in oral squamous carcinoma subjects compared to premalignant cases and controls, indicating the presence and aggravation of systemic inflammation.</p><p><strong>Conclusion: </strong>The study revealed that subjects with oral squamous cell carcinoma have lower TAP 1 and TAP 2 gene expression than premalignant control subjects, thus affecting MHC-I processing, which ultimately affects the functioning of the immune system. These results have the potential to improve our understanding of disease pathophysiology and provide more targeted treatment options.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening Co-Diagnostic Genes for Lung Adenocarcinoma and Myocardial Infarction and Analysis of the Molecular Functions and Drug Value of the Genes.","authors":"Nannan Du, Mengting Liang, Zongjun Liu","doi":"10.2174/0118715303374928250130113050","DOIUrl":"https://doi.org/10.2174/0118715303374928250130113050","url":null,"abstract":"<p><strong>Background: </strong>Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer, and myocardial infarction (MI) is an acute cardiovascular disease resulting from the disruption of coronary blood supply. Recent studies have suggested that these two diseases may share common molecular mechanisms.</p><p><strong>Aim: </strong>The aim of this study was to discover common diagnostic genes for LUAD and MI and analyze their molecular functions and potential drug values by applying bioinformatics analysis.</p><p><strong>Objective: </strong>The objective was to provide a theoretical basis for further research on the pathological mechanisms of LUAD and MI, contributing to the development of novel diagnostic and therapeutic strategies for the two diseases.</p><p><strong>Methods: </strong>In this study, the datasets of LUAD and MI were obtained from TCGA and GEO databases, and differential expression analysis was performed to screen significantly differentially expressed genes (DEGs). Subsequently, disease-related genes were identified using WGCNA analysis, and the biological functions of these genes were explored by functional enrichment analysis. After screening key genes using the protein-protein interaction (PPI) network and the cytoHubba algorithm, biomarkers were determined by LASSO and SVM-RFE machine-learning methods. Finally, immune infiltration analysis and drug prediction were performed, and biomarker expression was verified by single-cell sequencing analysis.</p><p><strong>Results: </strong>A total of 158 differentially upregulated genes were identified between LUAD and MI. WGCNA analysis screened 86 genes that were significantly associated with both diseases and were enriched in an inflammatory response and immune regulation-related pathways, such as the IL-17 signaling pathway. Ten significant genes were identified by the PPI network and cytoHubba and then reduced to 4 using LASSO and SVM-RFE. Noticeably, MMP9 was significantly overexpressed in both diseases. Immune infiltration analysis showed that MMP9 was significantly related to multiple immune cell infiltration. Drug prediction and molecular docking analysis predicted Ilomastat and Osthole as the potential target drugs. Single-cell sequencing analysis revealed that MMP9 was high-expressed in the macrophages in LUAD tissues.</p><p><strong>Conclusion: </strong>This study identified MMP9 as a common diagnostic gene and potential therapeutic target for both LUAD and MI and revealed its role in inflammation and immune regulation through comprehensive bioinformatics analysis. These findings provided a theoretical basis for further research on the pathological mechanisms of LUAD and MI, contributing to the development of novel diagnostic and therapeutic strategies.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sars-Cov-2 Infection as Catecholamin Crisis in Pheocreomocitoma: A Case Report.","authors":"Roberto Novizio, Andrea Corsello, Gaetano Emanuele Rizzo, Alfredo Pontecorvi, Pietro Locantore","doi":"10.2174/0118715303348376250103113426","DOIUrl":"https://doi.org/10.2174/0118715303348376250103113426","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The primary presentation of SARS-CoV-2 infection is viral pneumonia, which may be complicated by acute respiratory distress syndrome, although several other manifestations can occur.. Endocrine implications have been described. Pheochromocytomas are rare tumors mainly originating in the adrenal medulla. Symptoms are primarily due to catecholamine overproduction and abrupt release. Catecholamine release is unregulated and could be continuous or paroxysmal. Some conditions (i.e., stress, physical exercise, or specific foods) can trigger catecholamine release. Sars-CoV-2 infections have not been previously described as precipitators of adrenergic crises in pheochromocytoma patients. In this study, we report a case of adrenal crisis of a patient affected by pheochromocytoma in the context of Sars-CoV-2 infection.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Case report: &lt;/strong&gt;A 63-year-old Caucasian male known for right adrenal pheochromocytoma waiting for surgical removal was admitted to the Emergency Department (ED) in March 2021 for a fainting episode and hypertensive crisis that he never experienced before. The patient had a known medical history of type 2 mellitus diabetes and hypercholesterolemia treated by slow-release metformin 500 mg/day and atorvastatin 40 mg/day and was not vaccinated for Sars-CoV-2. Two months before, the patient was hospitalized in another hospital for myocardial infarction with non-obstructive coronary arteries, and a chest-abdomen TC scan showed a right adrenal lodge occupied by coarse formation. In the 24-h urine sample, metanephrines were &gt;5000 μg/24h and Normetanephrines &gt;2500 μg/24h. Scintigraphy with 123I-Metaiodobenzylguanidine (MIBG) showed accumulation in right adrenal gland formation, confirming the suspicion of pheochromocytoma. No further areas of pathological uptake were present. Fort that, the patient was started on alpha-blockers (doxazosin 2 mg twice/day). Two weeks later, the patient was also prescribed metoprolol 50 mg twice/day. When admitted to the Emergency Department (ED), Blood Pressure (BP) was 210/108 mmHg with a heart rate of 105 bpm. A routine nasopharyngeal swab for Sars-CoV-2 was performed, resulting positive. After an extra dosage of 2 mg of doxazosin and 20 mg of nifedipine, symptoms addressed to catecholamine release disappeared. Being positive for Sars-CoV-19, the patient was transferred to the infectious diseases department. High mean BP was demonstrated at the control profile. Doxazosin was increased to 4 mg twice a day with a good effect on BP and tachycardia. After 10 days, the SARS-CoV-2 swab result was negative, and the patient was discharged with normal vital parameters and instructions to continue the increased dose of doxazosin. No other crisis was reported until surgery, which was performed without any complications after 1 month.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Since the adrenal crisis is a life-threatening condition, we suggest close BP monitoring and therapeutic adher","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}